Genzyme
Osiris Leaps on $1.38 Billion Genzyme Stem-Cell Deal
Genzyme announced that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult mesenchymal stem cell treatments that hold significant potential to treat a wide range of diseases. These stem-cell products are designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar [...]
PTC Inks $437M Gene Therapy Deal With Genzyme
Image via Wikipedia
Talk about a good week for PTC.
A day after announcing the Cystic Fibrosis Foundation is dropping $25M on PTC124 (PTC’s novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations) and funding the phase 2 trial, Genzyme and PTC Therapeutics announced an exclusive global collaboration to develop [...]
Blow to Biogenerics: Genzyme Can’t Scale Myozyme
(From The Boston Globe via PharmaLot)
The FDA set an extremely high bar yesterday for biosimilars when it ruled Genzyme could not get clearance to manufacture Myozyme (alglucosidase alfa) to treat Pompe disease (a rare genetic disease that inhibits the breakdown of glycogen in muscles into glucose) at the 2000L scale as opposed to the 160L [...]
Top Biopharma Deals Q1 ‘08
It’s a just a quarter of the way into 2008 and it is clear the both large
biotech and pharma have holes to fill in thier pipeline. Six deals have
already been inked that total over a half a billion bio-dollars each.
Below are 4 of the top deals thus far:
Genzyme/Isis ($1,900M) - Genzyme paid Isis $175M in
cash [...]
Recent Comments